FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2399278318> ?p ?o ?g. }

• W2399278318 endingPage "8" @default.
• W2399278318 startingPage "1" @default.
• W2399278318 abstract "Background . This analysis examined the efficacy of fidaxomicin versus vancomycin in 406 Canadian patients with Clostridium difficile infection (CDI), based on data from 2 randomized, clinical trials. Methods . Patients received fidaxomicin or vancomycin 1. Patients were assessed for clinical response recurrence of infection and sustained clinical response for 28 days after treatment completion. Patients at increased risk of recurrence were subjected to subgroup analyses. Results . Clinical response rates for fidaxomicin (90.0%) were noninferior to those with vancomycin (92.2%; 95% confidence interval for difference: −7.7, 3.5). However, fidaxomicin-treated patients had lower recurrence (14.4% versus 28.0%,<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M1><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle=italic>0.001</mml:mn></mml:math>) and higher sustained clinical response (77.1% versus 66.3%,<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M2><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle=italic>0.016</mml:mn></mml:math>). Compared with vancomycin, fidaxomicin was associated with lower recurrence rates in all subgroups, reaching statistical significance in patients with age ≥ 65 years (16.0% versus 30.9%,<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M3><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle=italic>0.026</mml:mn></mml:math>), concomitant antibiotic use (16.2% versus 38.7%,<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M4><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle=italic>0.036</mml:mn></mml:math>), and non-BI strains (11.8% versus 28.3%,<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M5><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle=italic>0.004</mml:mn></mml:math>). Higher sustained clinical response rates were observed for fidaxomicin compared with vancomycin in all subgroups; this was statistically significant in the non-BI subgroup (82.8% versus 69.1%,<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M6><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn fontstyle=italic>0.021</mml:mn></mml:math>). Conclusions . In Canadian patients, fidaxomicin was superior to vancomycin in sustaining clinical response and reducing CDI recurrence." @default.
• W2399278318 created "2016-06-24" @default.
• W2399278318 creator A5002371143 @default.
• W2399278318 creator A5002574698 @default.
• W2399278318 creator A5010148072 @default.
• W2399278318 creator A5012866996 @default.
• W2399278318 creator A5024258790 @default.
• W2399278318 creator A5031717138 @default.
• W2399278318 creator A5042929688 @default.
• W2399278318 date "2016-01-01" @default.
• W2399278318 modified "2023-09-25" @default.
• W2399278318 title "Fidaxomicin versus Vancomycin in the Treatment of<i>Clostridium difficile</i>Infection: Canadian Outcomes" @default.
• W2399278318 cites W1531222087 @default.
• W2399278318 cites W1916481354 @default.
• W2399278318 cites W1969144992 @default.
• W2399278318 cites W1975385560 @default.
• W2399278318 cites W1992722926 @default.
• W2399278318 cites W2007823161 @default.
• W2399278318 cites W2044370864 @default.
• W2399278318 cites W2074586142 @default.
• W2399278318 cites W2077575064 @default.
• W2399278318 cites W2102219089 @default.
• W2399278318 cites W2102472050 @default.
• W2399278318 cites W2109743785 @default.
• W2399278318 cites W2113556993 @default.
• W2399278318 cites W2115933529 @default.
• W2399278318 cites W2119278807 @default.
• W2399278318 cites W2119723188 @default.
• W2399278318 cites W2123776003 @default.
• W2399278318 cites W2130150046 @default.
• W2399278318 cites W2131038214 @default.
• W2399278318 cites W2139364762 @default.
• W2399278318 cites W2139754977 @default.
• W2399278318 cites W2144282350 @default.
• W2399278318 cites W2144646532 @default.
• W2399278318 cites W2145363179 @default.
• W2399278318 cites W2147511770 @default.
• W2399278318 cites W2147561159 @default.
• W2399278318 cites W2152855878 @default.
• W2399278318 cites W2154774987 @default.
• W2399278318 cites W2155293017 @default.
• W2399278318 cites W2156891220 @default.
• W2399278318 cites W2158871837 @default.
• W2399278318 cites W2163423623 @default.
• W2399278318 cites W2165050668 @default.
• W2399278318 cites W2165833212 @default.
• W2399278318 cites W2166602148 @default.
• W2399278318 cites W2166660180 @default.
• W2399278318 cites W2167309979 @default.
• W2399278318 cites W2167766152 @default.
• W2399278318 cites W2168002465 @default.
• W2399278318 cites W2168453790 @default.
• W2399278318 cites W2170699724 @default.
• W2399278318 cites W4367720797 @default.
• W2399278318 doi "https://doi.org/10.1155/2016/8048757" @default.
• W2399278318 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4904592" @default.
• W2399278318 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27366179" @default.
• W2399278318 hasPublicationYear "2016" @default.
• W2399278318 type Work @default.
• W2399278318 sameAs 2399278318 @default.
• W2399278318 citedByCount "15" @default.
• W2399278318 countsByYear W23992783182017 @default.
• W2399278318 countsByYear W23992783182018 @default.
• W2399278318 countsByYear W23992783182019 @default.
• W2399278318 countsByYear W23992783182020 @default.
• W2399278318 countsByYear W23992783182021 @default.
• W2399278318 countsByYear W23992783182022 @default.
• W2399278318 countsByYear W23992783182023 @default.
• W2399278318 crossrefType "journal-article" @default.
• W2399278318 hasAuthorship W2399278318A5002371143 @default.
• W2399278318 hasAuthorship W2399278318A5002574698 @default.
• W2399278318 hasAuthorship W2399278318A5010148072 @default.
• W2399278318 hasAuthorship W2399278318A5012866996 @default.
• W2399278318 hasAuthorship W2399278318A5024258790 @default.
• W2399278318 hasAuthorship W2399278318A5031717138 @default.
• W2399278318 hasAuthorship W2399278318A5042929688 @default.
• W2399278318 hasBestOaLocation W23992783181 @default.
• W2399278318 hasConcept C11413529 @default.
• W2399278318 hasConcept C126322002 @default.
• W2399278318 hasConcept C2778980435 @default.
• W2399278318 hasConcept C2779489039 @default.
• W2399278318 hasConcept C2781342628 @default.
• W2399278318 hasConcept C2994496256 @default.
• W2399278318 hasConcept C33923547 @default.
• W2399278318 hasConcept C44249647 @default.
• W2399278318 hasConcept C501593827 @default.
• W2399278318 hasConcept C523546767 @default.
• W2399278318 hasConcept C54355233 @default.
• W2399278318 hasConcept C71924100 @default.
• W2399278318 hasConcept C86803240 @default.
• W2399278318 hasConcept C89423630 @default.
• W2399278318 hasConceptScore W2399278318C11413529 @default.
• W2399278318 hasConceptScore W2399278318C126322002 @default.
• W2399278318 hasConceptScore W2399278318C2778980435 @default.
• W2399278318 hasConceptScore W2399278318C2779489039 @default.
• W2399278318 hasConceptScore W2399278318C2781342628 @default.
• W2399278318 hasConceptScore W2399278318C2994496256 @default.
• W2399278318 hasConceptScore W2399278318C33923547 @default.

• next